Point of Care Hematology Diagnostics Market Report 2025

The point of care hematology diagnostics market size has grown strongly in recent years. It will grow from $2.66 billion in 2024 to $2.9 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth during the historic period can be attributed to the increasing prevalence of hematological disorders, the expansion of decentralized healthcare settings, growing focus on early disease detection, rising healthcare expenditures in emerging markets, and the growing adoption of portable diagnostic devices.

The point of care hematology diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.05 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth during the forecast period can be attributed to the increasing adoption of personalized medicine, rising demand for immediate clinical decision-making, growing use of home healthcare diagnostics, higher prevalence of blood-related disorders, and heightened awareness of preventive healthcare. Key trends expected during the forecast period include advanced connectivity features in hematology analyzers, innovations in sample preparation methods, integration of artificial intelligence in diagnostic tools, developments in single-cell analysis, adoption of cloud-based data platforms, and advancements in lab-on-a-chip solutions.

The increasing prevalence of blood disorders is expected to drive significant growth in the point-of-care hematology diagnostics market. Blood disorders are the conditions affecting red blood cells, white blood cells, platelets, or plasma are rising largely due to the growing incidence of chronic diseases, which directly impact blood health and necessitate regular monitoring. Point-of-care hematology diagnostics facilitate timely detection and management of these disorders by providing rapid, accurate results at or near the patient care site, enabling faster clinical decisions and improved disease management. For example, in April 2024, the Perth Blood Institute, an Australia-based non-profit, reported that the number of individuals diagnosed with hemophilia increased to 257,146 in 2022, up from 233,577 in 2021. This trend underscores the critical role of point-of-care hematology diagnostics in addressing the rising incidence of blood disorders.

Key companies in this market are developing advanced solutions, such as cartridge-based AI-powered hematology analyzers, to deliver rapid and precise on-site blood analysis. These compact devices utilize single-use reagent cartridges and artificial intelligence algorithms to perform complete blood counts (CBC) and other analyses directly at the point of care. For instance, in September 2024, Zoetis Inc., a US-based veterinary health company, launched Vetscan OptiCell, a cartridge-based, AI-powered hematology analyzer for veterinary use. This system provides rapid, reference-quality CBC results within minutes, while minimizing maintenance and hands-on time. It features AI-driven image analysis and viscoelastic focusing technology to accurately align cells, classify blood cells, and automatically detect abnormalities, ensuring reliable and efficient diagnostics.

In June 2023, Mars Inc., a US-based pet company, acquired Heska Corporation for an undisclosed amount. This acquisition expands Mars’ veterinary diagnostics capabilities and strengthens its position in advanced animal healthcare by leveraging Heska’s point-of-care hematology and specialty diagnostic solutions.

Major players in the point of care hematology diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Sysmex Corporation, HORIBA Ltd., Nova Biomedical Corp., S.D. Sight Diagnostics Ltd., EKF Diagnostics Holdings plc., Medsource Ozone Biomedicals Pvt. Ltd., BioSystems S.A., Chengdu Seamaty Technology Co. Ltd., Drucker Diagnostics LLC, Diamond Diagnostics Inc., DIAGON Kft., BioMedomics Inc., Norma Instruments Zrt., PixCell Medical Technologies Ltd.

North America was the largest region in the point of care hematology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in point of care hematology diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the point of care hematology diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Point-of-care hematology diagnostics refer to medical tests conducted at or near the site of patient care to quickly evaluate blood-related conditions, such as anemia, infections, or clotting disorders. These tests deliver rapid and accurate hematological results to support timely clinical decisions, particularly in emergency or resource-limited settings. This approach minimizes the reliance on centralized laboratory testing and accelerates diagnosis and treatment.

The primary types of point-of-care hematology diagnostics include complete blood count (CBC), coagulation testing, hemoglobin testing, anemia diagnosis, and others. A CBC measures various blood components, including red blood cells, white blood cells, hemoglobin, hematocrit, and platelets, helping to assess overall health and detect a wide range of disorders. These diagnostics are available as consumables and systems and are offered in both prescription-based and over-the-counter formats, serving end users such as diagnostic centers, hospitals, blood banks, transfusion centers, and other healthcare facilities.

The point-of-care hematology diagnostics market research report is one of a series of new reports that provides point-of-care hematology diagnostics market statistics, including point-of-care hematology diagnostics industry global market size, regional shares, competitors with a point-of-care hematology diagnostics market share, detailed point-of-care hematology diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care hematology diagnostics industry. This point-of-care hematology diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The point of care hematology diagnostics market consists of revenues earned by entities by providing services such as rapid blood testing, decentralized diagnostic solutions, and home-based blood monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The point of care hematology diagnostics market also includes sales of portable hematology analyzers, cartridges and test kits, lancets, and reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.